Challenges in cell culture platform development of mAb production with site-specific incorporation of non-natural amino acid for ADC generation by Lin, Weimin et al.
 Poster Number 148 
CHALLENGES IN CELL CULTURE PLATFORM DEVELOPMENT OF mAb PRODUCTION WITH SITE-
SPECIFIC INCORPORATION OF NON-NATURAL AMINO ACID FOR ADC GENERATION 
 
Weimin Lin, Cell Culture Development, Ambrx, San Diego, CA 
weimin.lin@ambrx.com  
Yingchun Lu, Ambrx 
Le You, Ambrx 
Kellen Dragan, Ambrx 
Mark Shimazu, Ambrx 
 
 
Key Words: cell culture platform, non-natural amino acids, ADC, CHO-K1, tRNA, CRISPR/Cas9, cell line 
engineering, chemically defined media, process development 
 
Ambrx’s mammalian expression platform (EuCODE) enables non-native amino acids (nnAAs) through an 
expanded genetic code to both generate novel bio-therapeutics and to optimize the performance of antibody 
drug conjugate (ADC), therapeutic proteins, monoclonal antibodies (mAbs), and, bi- and multi-specific 
medicines. While the ability to control the defined Drug-to-Antibody Ratio (DAR) and payload site can provide an 
advantage to an ADC, the site-specific incorporation of the NAAs into the antibody heavy chain introduces a 
unique challenge for antibody production. 
 
To enable higher performance benchmarks in time and resources for process development with stringent 
product quality requirements, a proprietary cell culture platform is being developed and demonstrated fast-track 
development of high-quality, high-titer processes for producing recombinant proteins from CHO cells.  
We successfully generated a CHO-K1 cell line, stably expressing engineered amber suppressor tRNA and its 
cognate tRNA synthetase specific for non-natural amino acid para-acetyl phenylalanine (pAF), to achieve high 
production of monoclonal antibodies (mAbs) containing nnAAs. The stable cell lines were further evolved using 
CRISPR/Cas9 genome editing technology to sequentially knock out selected genes in glutamine synthesis, and, 
apoptosis pathways to improve selection efficiency and prevent loss of viable cell mass in production cultures, 
respectively.  Inhibition of apoptosis pathway leads to dramatic increase in viable cell mass and results in 
extended production time and increased productivity.  
 
In this presentation, we will discuss the challenges in cell culture platform development including cell line 
engineering, systematic DoE-based approaches on optimal chemically defined media and cell culture 
processes, and, strategies for scale up to clinical and commercial scales. 
 
